Mats-Olof Wallin

Director Financiero/CFO en OxThera AB .

73 años

Health Technology

Consumer Services

Cargos activos de Mats-Olof Wallin

Empresas	Cargo	Inicio	Fin
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Director Financiero/CFO	01/01/2020	-

Empresas	Cargo	Inicio	Fin
KARO PHARMA AB (PUBL)	Director Financiero/CFO	01/01/2018	01/10/2019
SWEDISH ORPHAN BIOVITRUM AB	Director Financiero/CFO	08/04/2013	20/07/2018
BIOTAGE AB	Director Financiero/CFO	17/05/2010	01/01/2012
BIOTAGE AB	Public Communications Contact	17/05/2010	01/01/2012

University of Uppsala

Undergraduate Degree

Internacional

Suecia

Operativa

Director of Finance/CFO	4
Public Communications Contact	1
Undergraduate Degree	1

Sectorial

Health Technology	5
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas privadas	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology

Empresas privadas

Health Technology